investing in global health “best buys” and priorities for action in developing countries fogarty...
TRANSCRIPT
Investing in Global Health“Best Buys” and Priorities for Action in
Developing Countries
Fogarty International Center of the U.S. National Institutes of Health, the World Bank, the World Health Organization, and the Population Reference
BureauGlobal Health Mini-University, 27 October 2006
2
Presentation Overview
• Rationale for Disease Control Priorities• Objectives of the Project• Burden of Disease• Need for Cost-Effective Interventions• Cost-Effectiveness Analysis Results• Recommendations and Pearls
3
Changes in Life Expectancy by World Bank Region
0
10
20
30
40
50
60
70
80
90
1960 1990 2002 2020
Lif
e E
xpec
tan
cy,
Yea
rs
Low - andMiddleIncomeHigh-Income
World
Region
4
In spite of improvement in the 20th century, progress has been uneven
44
69
50
4044
63
76
65
50
58
65
78
67
46
63
0
20
40
60
80
100
LMICs HICs World Sub-SaharanAfrica
South Asia
(Lif
e E
xpec
tan
cy)
Yea
rs
1960 1990 2002
5
76
87
5436
10
non-communicable diseasescommunicable diseasesinjuries
76
87
Developing countries carry a double
disease burden
5436
10
non-communicable diseasescommunicable diseasesinjuries
Low- and Middle-income countries High-income countries
Percentage of deaths by cause
6
The 20th century witnessed the largest global increase in life expectancy in history.
Will the 21st century build on the successes of the last century, plateau, or will we see a retreat from the gains of the past?
7
Will this be the century of disease?
• HIV/AIDS• Cardiovascular disease• The persistence of high, but
preventable levels of malaria, TB, diarrhea, and pneumonia
• Avian flu/emerging infections/pandemics
Four challenges:
8
The Disease Control Priorities Project offers priorities for action that will lead to healthier and longer lives in developing countries.
9
What is the DCPP?
DCPP is an alliance of organizations/partners designed to review, generate and disseminate information on how to improve population health in developing countries.
2
• Fogarty International Center, US National Institutes of Health
• World Bank
• World Health Organization
• Population Reference Bureau
• Supported by the Bill & Melinda Gates Foundation
10
Objectives of DCPP (1)
Inform health sector decision-making in developing countries to decrease illness, disability, death, and economic burden by:
Developing an evidence base to inform decision-making by:
• Providing estimates of the cost-effectiveness and impact of single interventions and packages
• Collaborating in defining disease burdens globally and regionally
• Summarizing implementation experience in different regions and globally
4
11
Objectives of DCPP (2)
Communicating major findings
• Suggesting the “best buys” and the “worst buys” in any given setting
• Disseminating the results widely to multiple audiences
• Stimulating national priority setting and program implementation
5
12
The best health care solutions:
• Target major causes of death, disability and illness in developing countries;
• Are cost-effective; and• Are available.
13
How can DCPP improve health globally?
• Helps countries choose the best health care investments.
• Recommends 10 best health buys that are highly cost-effective in many settings.
• Identifies health policy priorities for developing countries.
• Suggests changes to infrastructure (health systems, financing, policies, R&D) to maximize results.
14
Burden of Disease (BOD)
BOD analysis provides a standardized framework for integrating all available information on mortality, causes of death, individual health status, and condition-specific epidemiology to provide an overview of the levels of population health and the causes of loss of health
Consistent, comprehensive descriptive epidemiology Common metric or summary measure (e.g. DALY), that allows for comparisons across diseases and interventions
15
The DALY:
• Combines years of life lost to premature mortality and years spent with a disability or illness
• Provides a metric of disease impact (“burden of disease”) reflecting both mortality and morbidity
• For example, diabetes in high income countries comprises 2.1% of deaths and 2.8% of DALYs
16
The cause distribution of burden of disease, by region, 2001
Source: Mathers, Lopez & Murray, Burden of Disease Volume, 2006.
17
0 50 100 150 200 250 300 350 400 450 500 550
High income
Europe and CentralAsia
Latin America andCaribbean
Middle East andNorth Africa
East Asia and Pacific
South Asia
Sub-Saharan Africa
DALYs per 1,000
HIV/AIDS
Other infectious and parasitic*
Maternal, perinatal andnutritionalCardiovascular diseases
Cancers
Neuropsychiatric
Other noncommunicable
Unintentional injuries
Intentional injuries
17
BOD and Comparative Risk Assessment (CRA)
• BOD reflects impact of illness and disability
• Risk factors tell us the causes behind disease and disability
• Comparative risk assessment shows potential gains in population health from reducing the risk exposures
18
Global Burden of Disease Study 1990:DALYs attributable to 10 selected risk factors
Risk factor Percent global total
Malnutrition 16%Poor water/sanitation 7%Unsafe sex 4%Alcohol 4%Occupation 3%Tobacco 3%Hypertension 1%Physical inactivity 1%Illicit drugs 0.6%Air pollution 0.5%
Intervention Cost-Effectiveness Summary of key
messages
20
Objective: Improve Quality of Health Spending
• Provide information on the “price” of buying health through different interventions
• Policymakers can combine this information with other considerations to determine how best to improve health
21
Neglected opportunities
Cost-effective interventions used widely
Interventions for which
scaling up is inefficient
Interventions to reconsider
Current Coverage
Cos
t E
ffec
tiven
ess High
Low
Low High
Identifying the Efficiency of Current and Potential Interventions
22
Interventions Covered
• Cost effectiveness of 257 interventions in $/DALY averted (DCP1 had 68)
• Cost effectiveness of an additional 62 interventions using other metrics (26 in DCP1)
• Also provide information on• Cost-effectiveness by region• Target population• Personal versus population• Avertable burden• Quality of evidence
23
Reduce Fatal and Disabling Injuries
Injuries and violence caused more than 5 million deaths in 2001, with an especially
heavy toll on young men.
• Install speed bumps at dangerous intersections.
• Increase penalties for speeding; awareness through media; and law enforcement.
24
Traffic Accidents: Interventions to Reduce Injuries
0
20
40
60
80
100
120
140
160
180
EAP ECA LAC MENA SAR SSA
US
$/D
AL
Y
Increased penalties forspeeding and othereffective road safetymeasures, combinedwith media coverageand betterenforcement
Speed bumps
25
Traffic Accidents: Interventions to Reduce Injuries
0
1000
2000
3000
4000
5000
6000
EAP ECA LAC MENA SAR SSA
US
$/D
ALY
Enforcement ofseatbelt lawsChild restraints
26
Stop the Spread of Tuberculosis
Tuberculosis (TB) is spreading into new populations and resisting treatment
• Treat active TB cases with short-course chemotherapy.
• Increase case detection.• Manage multidrug resistant TB with
new drugs and drug combinations.
27
Cost effectiveness (US$/DALY)
Tuberculosis
short-course chemotherapy (DOTS) of infectious TB (allowing for transmission, non-HIV+) for endemic TBshort-course chemotherapy (DOTS) of infectious TB (no allowing for transmission, non-HIV+) for endemic TB
short-course chemotherapy (DOTS) of non-infectious TB (non-HIV+) for endemic TB
short-course chemotherapy (DOTS) of infectious TB (allowing for transmission, non-HIV+) for epidemic TB
Tuberculosis: Short-course Chemotherapy
0
50
100
150
200
250
300
350
EAP ECA LAC MENA SAR SSA
US
$/D
AL
Y
Infectious TB (non-HIV+) forendemic TB (allowing fortransmission)
Infectious TB (non-HIV+) forendemic TB (not allowing fortransmission)
Infectious TB (allowing fortransmission, non-HIV+) forepidemic TB
28
Tuberculosis: Management of Drug Resistance
0
200
400
600
800
1,000
1,200
US
$/D
AL
Y Endemic TB (standardregimen)
Endemic TB (individualizedregimen)
Epidemic TB (standardregimen)
29
Control Malaria
Malaria claims the lives of 1 million children yearly, and it threatens nearly one-half of the world’s population.
• Provide universal access to insecticide-treated nets in areas where malaria is endemic.
• Expand intermittent preventive treatment for pregnant women.
• Subsidize artemisinin combination therapy to ensure effective treatment.
30
Malaria: Residual Household Spraying
0
5
10
15
20
25
30
SSA
US
$/D
AL
Y
Melathion, 1 round
DDT, 1 round
Deltamethrin, 1 round
Lambda-cyhalothrin targetdose, 1 round
Melathion, 2 round
DDT, 2 round
Deltamethrin, 2 round
Lambda-cyhalothrin targetdose, 2 round
31
Ensure Healthier Children
More than 13 million children (including stillbirths) die each year in developing countries.
• Keep newborns dry, warm and clean.• Vaccinate children against major childhood
killers.• Monitor children’s health to prevent and treat
childhood pneumonia, diarrhea, and malaria.
32
Diarrheal Disease
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
EAP LAC MENA SAR SSA
US
$/D
AL
Y
Rotavirus immunization
Cholera immunization
Water and sanitation (urban,5 years)Water and sanitation (rural, 5years)Breastfeeding promotion
Oral rehydration therapy
33
Diarrheal Disease: CEA forBreastfeeding and Oral Rehydration
Therapy Interventions
0
500
1,000
1,500
2,000
2,500
3,000
EAP LAC MENA SAR SSA
US
$/D
AL
Y Breastfeeding promotion
Oral rehydration therapy
34
Childhood Illness: Interventions for Acute Respiratory Infections
0
500
1,000
1,500
2,000
2,500
EAP LAC MENA SA SSA
US
$/D
AL
Y Community-level casemanagement (non-severe)
Facility-level casemanagement (non-severe)
Entire case managementpackage
35
Combat Tobacco Use
Tobacco-related diseases are the fastest-growing cause of disease and disability in developing countries.
• Tax tobacco products to increase consumers’ costs by at least 33% to curb smoking.
• Restrict smoking in public places and workplaces.
• Provide nicotine replacement therapy and other cessation tools.
• Ban tobacco advertising.
36
Most smokers now live in low- and middle-income countries.
18%
82%
Where Smokers Live
Low- and Middle-income Countries
High-income Countries
37
Tobacco Use and Addiction
0
100
200
300
400
500
600
700
800
EAP ECA LAC MENA SA SSA
US$/D
AL
Y
Taxation - 33% priceincrease
Non-price interventions ateffectiveness of 2-10%
Nicotine ReplacementTherapy (NRT)
38
How Much Health Will a Million Dollars Buy?
Preventing and Treating Non-Communicable DiseaseService or Intervention DALYs Averted ($ per DALY)• Taxation of tobacco products 24,000-330,000 ($3-50)• Treatment of MI or heart 40,000-100,000 ($10-25)
attacks with an inexpensive setof drugs
• Treatment of MI with 1,300-1,600 ($600-750)inexpensive drugs plus
streptokinase• Lifelong treatment of heart 1,000-1,400 ($700-1,000)
attack and stroke survivors withdaily ‘polypill’
• Coronary artery bypass grafting <40 (>$25,000)in specific identifiable high riskcases
• Bypass surgery for less severe Very small (Very high) coronary artery disease
39
To get the best results:
• Choose interventions with low cost and high impact
• Strengthen health systems• Engage global partners and donors• Accelerate research and
development
40
“Pearls” for Your Consideration
• You don’t have to be rich to be healthy
• Policymakers can vastly improve quality of health spending by targeting interventions that are proven to be cost-effective
• Other?
41
Published April 2006, Oxford University Press.
25
42 26
Published April 2006, Oxford University Press.
43 27
Published April 2006, Oxford University Press.
Available in 7 languages
For more information, visit us at www.dcp2.org
45
“Pearls” for Your Consideration
• You don’t have to be rich to be healthy
• Policymakers can vastly improve quality of health spending by targeting interventions that are proven to be cost-effective
• Other?